[{"orgOrder":0,"company":"Toray Industries","sponsor":"Immunis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Nalfurafine","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Toray Industries \/ Immunis","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Immunis"}]

Find Clinical Drug Pipeline Developments & Deals by Toray Industries

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The partnership aims to focus on the clinical development of TRK-820 (nalfurafine hydrochloride), which is being evaluated for the treatment of Uremic Pruritus.

                          Brand Name : TRK-820

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 22, 2024

                          Lead Product(s) : Nalfurafine

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Immunis

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank